exposur
mucos
tissu
antigen
ag
result
induct
local
dissemin
respons
mucos
compart
well
system
immun
respons
manifest
presenc
agspecif
antibodi
ab
extern
secret
plasma
cell
variou
subset
mucos
system
lymphoid
tissu
thu
mucos
system
immun
compart
respond
normal
condit
vast
spectrum
environment
antigen
mainli
food
microbi
origin
describ
preced
chapter
enorm
antigen
load
result
strateg
distribut
cell
involv
uptak
process
present
ag
product
ab
cellmedi
immun
cmi
tcell
defens
front
line
mucos
tissu
almost
year
research
attempt
design
vaccin
administ
varieti
mucos
rout
rather
convent
parenter
inject
see
histor
introduct
begin
book
mucos
vaccin
mani
attract
featur
includ
easi
painless
administr
potenti
mass
immun
case
emerg
reduc
cost
product
storag
deliveri
import
mucos
vaccin
consist
promot
immun
respons
common
site
entri
infecti
agent
desir
featur
immedi
prompt
question
mucos
vaccin
becom
obviou
ensu
chapter
section
optim
dose
ag
mucos
vaccin
difficult
establish
low
unpredict
absorpt
intestin
surfac
interfer
quantit
superior
antigen
gastrointestin
gi
tract
therefor
need
develop
methodolog
would
mediat
preferenti
absorpt
desir
ag
obviou
furthermor
presenc
proteolyt
enzym
extern
secret
ag
need
protect
digest
see
chapter
enhanc
magnitud
qualiti
immun
respons
mani
mucos
adjuv
extens
test
experiment
anim
limit
degre
human
see
chapter
although
mani
substanc
display
desir
effect
accept
human
restrict
potenti
toxic
eg
cholera
toxin
ct
heatlabil
toxin
lt
e
coli
low
adjuvant
human
oppos
anim
eg
howev
mucos
adjuv
adequ
evalu
human
although
stimul
protect
immun
respons
mucos
infecti
agent
ultim
criterion
vaccin
perform
possibl
induct
state
system
unrespons
mucos
administ
antigenmucos
toleranceha
frequent
consid
neg
factor
accept
mucos
vaccin
mucos
toler
inde
fundament
featur
mucos
immun
system
critic
function
compon
effici
prevent
suppress
otherwis
unavoid
overstimul
entir
immun
system
environment
ag
thu
enhanc
protect
mucos
immun
respons
infecti
agent
sought
vaccinologist
suppress
system
respons
may
seem
paradox
discuss
next
outcom
mutual
exclus
hierarchi
qualiti
immun
respons
extens
studi
concern
origin
band
tlymphocyt
ultim
popul
mucos
tissu
secretori
gland
immun
rout
effect
induct
mucos
immun
respons
indic
common
mucos
immun
system
cmi
divid
two
function
distinct
compart
name
induct
versu
effector
site
network
highli
integr
fine
regul
outcom
mucos
tissu
encount
foreign
ag
pathogen
rang
mucos
plasma
ab
tcell
cmi
cytotox
tlymphocyt
ctl
respons
one
hand
system
anergi
mucos
toler
physiolog
divis
paramount
import
design
vaccin
effect
induct
protect
immun
within
mucos
immun
system
particular
humor
branch
experi
perform
anim
model
reveal
induct
site
present
certain
locat
gutassoci
speci
bronchusassoci
lymphoepitheli
tissu
galt
repres
peyer
patch
balt
respect
function
primari
sourc
precursor
cell
migrat
lymphat
blood
direct
extravas
popul
remot
mucos
tissu
gland
phillipsquagliata
lamm
scicchitano
et
al
recent
studi
suggest
induct
site
necessarili
restrict
peyer
patch
found
mainli
small
intestin
balt
bronchi
addit
site
identifi
nasal
mucosa
palatin
tonsil
organ
lymphoid
tissu
waldey
ring
nasopharynx
kuper
et
al
kiyono
larg
intestin
especi
rectum
genit
tract
number
type
cell
involv
immun
respons
product
primarili
ab
mediat
cytokin
chemokin
remark
differ
mucos
system
compart
immun
system
thu
secretori
iga
siga
differ
plasma
iga
term
specif
ab
activ
also
proport
polymer
versu
monomer
form
origin
secretori
tissu
versu
bone
marrow
plasma
cell
ontogeni
mucos
system
iga
compart
display
characterist
appar
independ
pattern
matur
adult
level
iga
reach
extern
secret
consider
earlier
month
year
blood
plasma
adolesc
allansmith
et
al
melland
et
al
experi
address
origin
mucos
ab
led
clear
conclus
overwhelm
proport
ab
produc
local
mucos
tissu
minor
fraction
deriv
circul
speci
includ
human
brandtzaeg
mestecki
mcghee
mestecki
et
al
induct
site
mucos
immun
respons
initi
describ
mucos
locat
small
intestin
peyer
patch
galt
phillipsquagliata
lamm
earlier
studi
shown
surgic
remov
peyer
patch
intestin
rat
affect
total
number
igacontain
cell
lamina
propria
develop
normal
antibodi
respons
intestin
immun
heatley
et
al
recent
mice
lack
peyer
patch
utero
treatment
receptorig
molecul
fusion
protein
develop
normal
mucos
system
immun
oral
immun
yamamoto
et
al
suggest
altern
induct
site
mucos
immun
present
galt
fact
lymphoid
follicl
term
isol
lymphoid
follicl
ilf
solitari
lymphoid
follicl
report
intestin
wall
rabbit
keren
et
al
guinea
pig
rosner
keren
human
moghaddami
et
al
neutra
et
al
structur
demonstr
mice
hamada
et
al
fagarasan
et
al
lorenz
et
al
number
matur
appear
trigger
lumen
stimuli
bacteri
flora
fagarasan
et
al
lorenz
et
al
organ
lymphoid
tissu
includ
palatin
lingual
nasopharyng
tonsil
waldey
ring
strateg
posit
begin
digest
respiratori
tract
continu
expos
ingest
inhal
antigen
nasopharyngealassoci
lymphoepitheli
tissu
nalt
possess
structur
featur
similar
lymph
node
peyer
patch
galt
brandtzaeg
ogra
see
chapter
exampl
tonsillar
crypt
possess
lymphoepithelium
contain
cell
select
antigen
uptak
well
b
cell
plasma
cell
antigenpres
cell
apc
distribut
cell
nasal
gastric
mucosa
lacrym
salivari
gland
similar
distribut
tonsil
suggest
tonsil
may
serv
sourc
precursor
iga
plasma
cell
found
upper
respiratori
digest
tract
furthermor
tonsillectom
children
display
lower
level
siga
antibodi
oral
polioviru
vaccin
children
intact
tonsil
ogra
other
shown
direct
unilater
inject
antigen
cholera
toxin
b
subunit
ctb
tetanu
toxoid
tt
tonsil
human
volunt
result
induct
mainli
mucos
immun
respons
manifest
appear
antigenspecif
igg
lesser
degre
igaform
cell
afc
inject
tonsil
et
al
recent
studi
confirm
preval
igg
antibodi
tonsil
demonstr
structur
display
featur
mucos
induct
effector
site
boyaka
et
al
therefor
tonsil
may
serv
induct
site
analog
galt
speci
organ
balt
also
note
airway
branch
experiment
anim
although
structur
rare
occur
human
pabst
sever
studi
emphas
import
induct
site
nasal
caviti
gener
mucos
system
immun
respons
may
exceed
magnitud
induc
oral
immun
bergquist
et
al
di
tommaso
et
al
gallichan
rosenth
lubeck
et
al
pal
et
al
russel
et
al
staat
et
al
introduc
nasal
caviti
usual
along
mucos
adjuv
ct
andor
ctb
viral
bacteri
antigen
induc
superior
immun
respons
extern
secret
saliva
surprisingli
femal
genit
tract
secret
rodent
rhesu
monkey
chimpanze
human
et
al
russel
mestecki
whether
antibodi
respons
also
induc
male
genit
tract
remain
determin
nevertheless
find
may
import
implic
design
vaccin
effect
induct
immun
respons
genit
tract
russel
mestecki
see
chapter
although
analog
studi
bacteri
antigen
perform
human
induct
genit
tract
immun
respons
nasal
immun
would
profound
implic
prevent
sexual
transmit
diseas
includ
aid
see
chapter
thu
differ
mucos
immun
rout
nasal
oral
induc
gener
mucos
immun
respons
although
rel
represent
domin
antibodi
isotyp
may
vari
circul
iga
afc
induc
nasal
vaccin
express
promiscu
profil
home
receptor
correspond
counterpart
rais
oral
rectal
immun
et
al
kantel
et
al
could
explain
fact
nasal
immun
appear
induc
siga
immun
broader
rang
mucos
tissu
oral
vaccin
although
investig
galt
mucos
iga
induct
site
primarili
center
peyer
patch
appendix
analog
follicular
structur
also
found
larg
intestin
especi
pronounc
accumul
rectum
langman
rowland
oleari
sweeney
potenti
import
rectal
lymphoid
tissu
iga
induct
site
sourc
iga
plasma
cell
precursor
suggest
sever
studi
predomin
cell
cell
lamina
propria
larg
intestin
clearli
diverg
rel
apport
iga
subclass
distribut
mucos
tissu
crago
et
al
kett
et
al
also
case
femal
genit
mucos
tissu
uteru
cervix
fallopian
tube
vagina
kutteh
et
al
suggest
rectal
lymphoid
tissu
may
import
sourc
iga
precursor
destin
genit
tract
potenti
import
rectal
lymphoid
tissu
induct
site
suggest
sever
studi
perform
human
nonhuman
primat
nhp
mice
rectal
immun
human
microbi
vaccin
eg
salmonella
typhi
variou
virus
induc
specif
antibodi
site
immun
also
saliva
secret
forrest
et
al
kozlowski
et
al
kozlowski
et
al
russel
mestecki
see
chapter
rectal
rout
immun
also
evalu
anim
experiment
rhesu
macaqu
immun
rectal
simian
immunodefici
viru
siv
display
tand
bcellmedi
immun
respons
includ
induct
antisiv
antibodi
lehner
et
al
lehner
et
al
mice
immun
rectal
ct
recombin
vaccinia
viru
express
siv
also
gener
humor
immun
respons
genit
tract
secret
well
serum
immun
rout
frequent
superior
either
gastric
vagin
rout
moldoveanu
et
al
haneberg
et
al
therefor
rectal
immun
rout
appear
effect
induct
local
also
gener
mucos
immun
respons
presenc
induct
site
tissu
howev
pronounc
speci
differ
respect
magnitud
immun
respons
induc
mice
display
vigor
respons
human
type
dose
antigen
well
frequenc
immun
may
partial
respons
observ
differ
studi
necessari
valid
limit
result
obtain
thu
far
male
includ
futur
immun
attempt
determin
whether
specif
immun
respons
gener
male
genit
tract
secret
earli
evid
select
mucos
home
reveal
find
rabbit
peyer
patch
b
cell
repopul
gut
becam
iga
plasma
cell
cebra
mesenter
lymph
node
oral
immun
experiment
anim
found
contain
antigenspecif
precursor
iga
plasma
cell
repopul
lamina
propria
gut
mammari
lacrym
salivari
gland
mcdermott
bienenstock
mcwilliam
et
al
mcwilliam
et
al
roux
et
al
evid
exist
cmi
human
provid
find
specif
siga
antibodi
secret
intestin
respiratori
genit
tract
well
tear
saliva
milk
observ
igasecret
cell
peripher
blood
follow
oral
immun
czerkinski
et
al
kantel
mestecki
mcghee
et
al
import
vaccin
develop
mention
earlier
immun
certain
induct
site
give
rise
humor
immun
respons
preferenti
manifest
certain
effector
site
result
subcompartment
cmi
exampl
repeat
nasal
immun
may
induc
elev
mucos
immun
respons
nasal
secret
also
saliva
hand
rectal
vaccin
may
induc
preferenti
immun
respons
site
immun
instanc
femal
genit
tract
number
studi
establish
mucos
addressin
cell
adhes
major
home
receptor
ligand
galt
berlin
et
al
holzmann
et
al
bell
issekutz
hamann
et
al
rott
et
al
see
chapter
addit
pair
repres
major
integrin
molecul
respons
lymphocyt
bind
express
high
endotheli
venul
hev
peyer
patch
holzmann
et
al
contrast
galt
lselectin
peripher
lymph
node
addressin
play
predomin
role
bind
naiv
lymphocyt
nalt
hev
csencsit
et
al
addit
studi
show
express
lselectin
effector
b
cell
induc
system
immun
small
proport
express
opposit
seen
enter
oral
rectal
immun
quidingjabrink
et
al
interestingli
effector
b
cell
induc
nasal
immun
display
promiscu
pattern
adhes
molecul
larg
major
cell
express
lselectin
quidingjabrink
et
al
clear
chemokin
directli
involv
mucos
home
effector
b
cell
exampl
loss
secondari
lymphoid
tissu
chemokin
slc
result
lack
naiv
tcell
dendrit
cell
dc
migrat
spleen
peyer
patch
gunn
et
al
thymusexpress
chemokin
teck
mediat
human
memori
cell
migrat
small
intestin
lamina
propria
gi
tract
fact
gut
home
hi
tcell
express
teck
receptor
zabel
et
al
reduct
level
total
intraepitheli
lymphocyt
iel
occur
small
intestin
mice
wurbel
et
al
addit
chemoattract
activ
cell
teck
effici
recruit
igaproduc
iggor
igmproduc
cell
spleen
peyer
patch
mesenter
lymph
node
bowman
et
al
lymphocyt
small
intestin
express
high
level
small
subset
lymphocyt
colon
kunkel
et
al
lymphocyt
tissu
includ
tonsil
lung
inflam
liver
normal
inflam
skin
inflam
synovium
synovi
fluid
breast
milk
semin
fluid
express
kunkel
et
al
consist
express
teck
express
also
restrict
small
intestin
kunkel
et
al
find
impli
restrict
role
lymphocyt
ligand
teck
small
intestin
add
support
function
compartment
immun
respons
differ
segment
gastrointestin
gi
tract
cmi
gener
recent
studi
shown
receptor
mucosaassoci
epitheli
chemokin
mec
select
express
iga
hi
iga
antibodysecret
cell
includ
circul
iga
plasmablast
almost
iga
plasma
cell
salivari
gland
small
larg
intestin
appendix
tonsil
lazaru
et
al
mec
attract
igaproduc
iggor
igmproduc
afc
intestin
lung
lymph
node
drain
bronchopulmonari
tree
oral
caviti
interestingli
cell
mucos
site
fail
respond
mec
suggest
distinct
chemokin
signal
need
mucos
home
b
versu
cell
concept
support
fact
whose
ligand
predominantli
restrict
small
intestin
thymu
express
fraction
iga
antibodyafc
almost
cell
small
intestin
small
percentag
plasma
cell
site
lazaru
et
al
mucos
rout
remain
prefer
one
vaccin
deliveri
induct
mucos
immun
howev
applic
antigen
mucos
area
lack
induct
site
intestin
peyer
patch
usual
ineffici
gener
dissemin
mucos
system
immun
respons
exampl
administr
nonrepl
antigen
conjunctiv
sac
vagina
intestin
loop
without
peyer
patch
result
local
low
immun
respons
review
see
mestecki
mestecki
mcghee
similarli
inject
antigen
lactat
mammari
salivari
gland
induc
siga
high
igg
antibodi
respons
milk
saliva
collect
immun
gland
secret
mucos
site
review
see
mestecki
concomit
igg
respons
plasma
suggest
inject
antigen
effector
site
consid
system
rather
mucos
immun
also
seem
case
antigen
inject
vicin
region
lymph
node
drain
certain
mucos
site
system
immun
gener
elicit
weak
humor
respons
extern
secret
cellular
respons
mucos
tissu
howev
extern
secret
femal
male
genit
tract
cervic
mucu
vagin
wash
preejacul
ejacul
contain
approxim
equal
level
iga
igg
mostli
circulatori
origin
see
chapter
therefor
system
immun
may
consider
import
induct
protect
respons
genit
tract
secret
furthermor
system
immun
conjug
polysaccharid
haemophilu
influenza
streptococcu
pneumonia
protein
tetanu
toxoid
tt
diphtheria
toxoid
dt
vaccin
induc
iga
igg
respons
plasma
secret
predominantli
igasecret
cell
peripher
blood
system
immun
volunt
fattom
et
al
recent
approv
coldadapt
live
attenu
influenza
viru
nasal
vaccin
flumist
medimmun
vaccin
inc
gaithersburg
md
june
system
immun
inactiv
split
influenza
viru
may
continu
vaccin
choicethu
system
immun
use
effect
rout
antigen
administr
ensu
protect
sever
mucos
contract
diseas
see
chapter
anoth
import
aspect
system
immun
concern
primari
effect
subsequ
mucos
immun
mani
previou
studi
indic
singl
even
repeat
immun
mucos
site
particularli
effect
mode
induct
vigor
immun
respons
instead
empir
experi
convincingli
demonstr
combin
mucos
immun
rout
eg
oral
rectal
elicit
better
respons
upmost
import
induct
respons
need
stimul
mucos
system
immun
goal
may
easili
attain
strictli
mucos
eg
oral
nasal
immun
howev
combin
system
prime
mucos
boost
like
lead
desir
outcom
previou
experi
moldoveanu
et
al
shown
system
prime
even
minut
dose
antigen
case
influenza
viru
follow
mucos
boost
elicit
better
mucos
system
immun
respons
mucos
immun
furthermor
system
prime
preclud
humor
cmi
respons
induc
mucos
boost
belyakov
et
al
distinct
advantag
sequenc
immun
revers
order
immunizationsmucos
prime
system
boostingmay
creat
undesir
complic
recent
phase
ii
clinic
trial
intramuscular
immun
live
recombin
canarypox
vaccin
could
induc
ctl
respons
system
mucos
compart
musey
et
al
studi
also
show
ctl
clone
establish
rectal
system
cell
one
vaccin
recipi
exhibit
similar
envspecif
respons
major
histocompat
complex
mhc
restrict
musey
et
al
result
suggest
parenter
vaccin
induc
ctl
local
site
infect
immun
respons
induc
transderm
skin
immun
scarif
smallpox
inocul
benenson
et
al
recent
skin
emerg
attract
target
vaccin
deliveri
exampl
depilatori
agent
tang
et
al
epiderm
powder
deliveri
system
shown
promot
mucos
system
immun
chen
et
al
interestingli
sever
studi
human
anim
model
glenn
et
al
shartonkerten
et
al
beignon
et
al
anjuer
et
al
guebrexabi
et
al
suggest
addit
system
immun
mucos
immun
achiev
topic
applic
intact
skin
vaccin
antigen
appropri
adjuv
adjuv
includ
ct
ctb
lt
nontox
mutant
lt
cpg
cytokin
promot
immun
cutan
vaccin
schartonkersten
et
al
beignon
et
al
chen
et
al
anjuer
et
al
suggest
enhanc
immun
respons
topic
vaccin
restrict
nativ
enterotoxin
epiderm
dendrit
cell
dc
langerhan
cell
appear
play
major
role
immun
respons
transcutan
immun
bacaestrada
et
al
extern
factor
vitamin
ultraviolet
radiat
b
also
report
regul
system
mucos
immun
transcutan
vaccin
enioutina
et
al
howev
mechan
underli
induct
mucos
immun
transcutan
vaccin
remain
elus
current
vaccin
exert
protect
effect
induct
specif
ab
mucos
ab
predominantli
iga
lesser
degre
igg
exhibit
protect
function
mechan
distinct
specif
antibodi
present
plasma
see
chapter
inhibit
microbi
adher
critic
initi
step
protect
host
mediat
specif
nonspecif
mechan
instanc
agglutin
abil
siga
specif
capsular
polysaccharid
h
influenza
seem
crucial
prevent
colon
h
influenza
kauppikorkeila
et
al
furthermor
anoth
nonspecif
mechan
inhibit
microbi
adher
due
presenc
carbohydr
chain
siga
molecul
bind
bacteria
antigen
davin
et
al
wold
et
al
siga
antibodi
shown
effect
neutral
virus
differ
step
infecti
process
particular
siga
specif
influenza
hemagglutinin
interfer
initi
bind
influenza
viru
target
cell
intern
intracellular
replic
viru
armstrong
dimmock
siga
neutral
catalyt
activ
mani
enzym
microbi
origin
neuraminidas
hyaluronidas
glycosyltransferas
igaspecif
proteas
well
toxic
activ
bacteri
enterotoxin
ct
relat
lt
e
coli
vitro
experi
employ
murin
polar
epitheli
cell
demonstr
antibodi
specif
rotaviru
hepat
viru
neutral
respect
virus
insid
epitheli
cell
mazanec
et
al
mazanec
et
al
evid
provid
similar
mechan
occur
vivo
burn
et
al
similarli
shown
transcytosi
primari
hiv
isol
block
polymer
iga
specif
hiv
envelop
protein
bomsel
et
al
mention
siga
antibodi
appear
import
limit
inflammatori
respons
mucos
surfac
fact
iga
antibodi
unabl
activ
complement
interfer
igmand
iggmedi
complement
activ
griffiss
goroff
russel
mansa
furthermor
iga
downregul
synthesi
well
enhanc
product
antagonist
lpsactiv
human
monocyt
wolf
et
al
wolf
et
al
addit
antiinflammatori
mechan
sigamedi
protect
recent
suggest
thu
siga
coloc
lp
apic
recycl
endosom
compart
prevent
lpsinduc
transloc
subsequ
proinflammatori
respons
fernandez
et
al
clear
demarc
induct
site
harbor
precursor
ctl
pctl
effector
site
includ
lamina
propria
epitheli
cell
activ
ctl
function
establish
administr
viru
gi
tract
result
higher
frequenc
pctl
peyer
patch
offit
et
al
london
et
al
exampl
reoviru
local
tcell
region
clearli
associ
increas
pctl
memori
b
cell
respons
london
et
al
oral
administr
vaccinia
rat
result
induct
virusspecif
ctl
peyer
patch
mesenter
lymph
node
issekutz
virusspecif
ctl
also
gener
mucosaassoci
tissu
oral
immun
reoviru
rotaviru
offit
et
al
london
et
al
high
frequenc
virusspecif
ctl
present
peyer
patch
earli
day
oral
immun
studi
suggest
oral
immun
live
viru
induc
antigenspecif
ctl
mucos
induct
effector
tissu
mucos
respons
system
lymphoid
tissu
well
vagin
gastrointestin
model
nhp
infect
siv
use
demonstr
success
vaccin
protect
sivhiv
may
requir
ctl
respons
mucosa
shown
vagin
inocul
nhp
low
dose
pathogen
siv
induc
ctl
could
develop
absenc
detect
antibodi
mcchesney
et
al
protect
delay
onset
diseas
upon
challeng
wilson
et
al
studi
shown
ctl
respons
gi
mucos
tissu
chronic
sivmacinfect
nhp
contain
level
ctl
compar
found
peripher
blood
lymph
node
schmitz
et
al
final
high
ctl
respons
develop
similar
rate
magnitud
peripher
mucos
lymphoid
tissu
primari
siv
infect
mucos
ctl
respons
may
predomin
later
cours
diseas
veazey
et
al
role
helper
th
cellderiv
cytokin
antibodi
cmi
respons
well
establish
thu
interleukin
il
trigger
cell
differenti
along
pathway
kobayashi
et
al
chan
et
al
micaleef
et
al
okamura
et
al
matur
cell
produc
also
known
mosmann
coffman
mediat
respons
associ
cmi
antibodi
subclass
mous
system
snapper
paul
hand
promot
differenti
cell
produc
mosmann
coffman
provid
effect
help
ige
antibodi
respons
coffman
et
al
finkelman
et
al
esser
radbruch
cell
quit
sensit
crossregul
thu
inhibit
cell
prolifer
bcell
isotyp
switch
stimul
gajewski
fitch
likewis
inhibit
secret
cell
allow
develop
cell
cell
subset
effect
helper
phenotyp
support
iga
isotyp
addit
ige
respons
mous
system
earlier
studi
establish
major
role
two
cytokin
induc
siga
b
cell
differenti
igaproduc
plasma
cell
mice
beagley
et
al
beagley
et
al
human
fujihashi
et
al
thu
also
shown
play
import
role
induct
iga
synthesi
especi
human
brier
et
al
defranc
et
al
final
high
frequenc
cell
produc
shown
mucos
effector
site
eg
intestin
lamina
propria
salivari
gland
iga
respons
occur
mega
et
al
taguchi
et
al
recent
studi
number
mucos
adjuv
vaccin
deliveri
system
shown
cytokin
also
import
mucos
siga
van
cott
et
al
marinaro
et
al
arulanandam
et
al
boyaka
et
al
find
underlin
import
siga
protect
host
mucos
surfac
solubl
toxin
allergen
well
intracellular
pathogen
requir
complementfix
antibodi
cmi
clear
cell
express
distinct
pattern
chemokin
receptor
bonnecchi
et
al
sallusto
et
al
kim
et
al
exampl
cxc
chemokin
receptor
preferenti
express
human
cell
clone
cell
express
lesser
extent
sallusto
et
al
imai
et
al
also
shown
mous
cell
cell
express
randolph
et
al
interestingli
cell
local
peripheri
tcell
zone
provid
help
nearbi
b
cell
bcell
follicl
randolph
et
al
extent
dichotomi
local
cell
occur
mucos
induct
effector
tissu
remain
determin
almost
viral
bacteri
pathogen
vaccin
would
desir
invad
mucos
tissu
cellmedi
antibodymedi
immun
would
effect
therefor
strike
current
vaccin
given
mucos
rout
recent
approv
nasal
flumist
influenza
vaccin
tabl
indic
earlier
chapter
mucos
deliveri
vaccin
overcom
number
problem
includ
vaccin
stabil
optim
antigen
dose
mucos
induct
site
effect
mucos
adjuv
enterotoxin
ie
ct
lt
unsuit
use
human
see
chapter
recent
mechan
action
poorli
understood
hamper
develop
safe
mucos
vaccin
howev
interest
mucos
vaccin
develop
increas
significantli
scientif
commun
led
public
adjuv
deliveri
system
mucos
vaccin
last
year
figur
studi
past
decad
identifi
site
action
sever
mechan
contribut
mucos
adjuvant
thu
mucos
adjuv
act
pattern
recognit
tolllik
receptor
tlr
epitheli
cell
figur
also
improv
antigen
deliveri
mucos
induct
site
increas
permeabl
epitheli
layer
target
cell
figur
recent
studi
establish
apc
key
player
develop
mucos
immun
fact
adjuv
includ
enterotoxin
cytokin
upregul
costimulatori
mhc
class
ii
molecul
express
macrophag
dc
thu
favor
interact
effector
b
cell
cong
et
al
yamomoto
et
al
gagliardi
et
al
staat
et
al
figur
addit
cytokin
secret
apc
includ
act
adjuv
induct
antibodi
cmi
respons
staat
et
al
bradney
et
al
cytokin
ligand
l
gmcsf
increas
number
dc
stimul
matur
williamson
et
al
dauer
et
al
also
promot
immun
mucos
vaccin
mucos
adjuv
stimul
matur
differenti
effector
b
cell
trigger
bcell
switch
product
siga
antibodi
figur
may
also
influenc
develop
target
respons
protect
intracellular
pathogen
respons
requir
protect
solubl
antigen
allergen
toxin
figur
describ
ct
lt
virtual
employ
mechan
list
earlier
enhanc
mucos
immun
confirm
enterotoxin
prefer
model
system
studi
regul
mucos
immun
mucos
adjuv
tabl
major
enterotoxin
produc
vibrio
cholera
escherichia
coli
ct
lt
respect
continu
studi
mucos
adjuv
see
chapter
account
nearli
public
mucos
vaccin
last
year
figur
b
subunit
molecul
bind
cell
surfac
gangliosid
thu
could
target
vaccin
mucos
epitheli
cell
ct
lt
could
also
enhanc
immun
respons
increas
permeabl
epitheli
membran
studi
earli
show
role
ct
bcell
switch
siga
antibodi
product
also
becom
clear
past
year
mucos
adjuv
play
major
role
differenti
cell
subsequ
respons
protect
intracellular
pathogen
toxin
regard
mucos
adjuv
activ
ct
oral
immun
mice
protein
antigen
ct
adjuv
involv
respons
xuamano
et
al
marinaro
et
al
vajdi
et
al
hand
oral
immun
lt
result
mix
respons
includ
chapter
mucos
vaccin
overview
takahashi
et
al
studi
chimera
ct
lt
shown
natur
subunit
enterotoxin
adp
ribosyltransferas
activ
direct
type
tcell
respons
bowman
clement
kweon
et
al
boyaka
et
al
establish
enterotoxin
upregul
costimulatori
mhc
class
ii
molecul
express
dc
thu
favor
interact
effector
b
cell
cong
et
al
yamamoto
et
al
gagliardi
et
al
ct
induc
secret
apc
cytokin
shown
promot
mucos
immun
mechan
resembl
mediat
ct
staat
et
al
mutant
ct
lt
mct
mlt
gener
amino
acid
substitut
gener
poor
adjuv
given
oral
rout
see
chapter
sinc
safeti
issu
associ
use
enterotoxin
nasal
adjuv
see
next
section
next
import
challeng
mucos
vaccinologist
devis
enzymat
inact
mct
mlt
capabl
act
mucos
adjuv
oral
vaccin
clear
stimul
via
pattern
recognit
tlr
favor
develop
mucos
immun
bacteri
eukaryot
dna
contain
immunostimulatori
sequenc
consist
short
palindrom
nucleotid
center
around
cpg
dinucleotid
core
eg
cpg
motif
krieg
see
chapter
clear
cpg
motif
induc
bcell
prolifer
ig
synthesi
well
secret
cytokin
ie
varieti
immun
cell
tigh
et
al
sinc
cpg
motif
creat
cytokin
microenviron
favor
respons
use
adjuv
stimul
antigenspecif
respons
redirect
harm
allerg
autoimmun
respons
inde
coinject
bacteri
dna
cpg
motif
dna
vaccin
protein
antigen
promot
respons
even
mice
preexist
immun
roman
et
al
klinman
et
al
import
chapter
cpg
motif
enhanc
system
well
mucos
immun
respons
given
mice
nasal
rout
mccluski
davi
moldoveanu
et
al
gallichan
et
al
oral
rout
mccluski
et
al
recent
studi
provid
evid
cpg
oligodeoxynucleotid
odn
could
also
induc
innat
immun
protect
femal
genit
tract
harandi
et
al
fact
vagin
administr
cpg
odn
rapidli
induc
rant
product
genit
tract
mucosa
harandi
et
al
vagin
cpg
odn
treatment
protect
mice
vagin
challeng
otherwis
lethal
dose
herp
simplex
viru
type
demonstr
induct
innat
immun
harandi
et
al
interest
two
innat
molecul
induc
cpg
ie
rant
report
bridg
mucos
innat
adapt
immun
system
see
next
section
zonula
occluden
toxin
zot
produc
toxigen
strain
vibrio
cholera
abil
revers
alter
intestin
epitheli
tight
junction
allow
passag
macromolecul
mucos
barrier
nasal
immun
mice
protein
antigen
recombin
zot
either
alon
fuse
maltosebind
protein
mbpzot
induc
high
antigenspecif
iga
antibodi
titer
plasma
well
vagin
intestin
secret
marinaro
et
al
moreov
zot
adjuv
induc
antigenspecif
igg
subclass
consist
antibodi
resembl
pattern
induc
lt
marinaro
et
al
zot
recent
shown
also
act
adjuv
rectal
immun
marinaro
et
al
studi
illustr
import
increas
permeabl
mucos
tissu
induct
mucos
immun
vaccin
mucos
vaccin
year
use
cytokin
chemokin
enhanc
immun
respons
mucos
vaccin
attract
strategi
least
two
reason
first
cytokin
chemokin
act
often
known
mechan
specif
interact
correspond
receptor
mucos
deliveri
cytokin
could
help
avoid
toxic
often
associ
larg
repeat
parenter
cytokin
dose
gener
need
marinaro
et
al
marinaro
et
al
huber
et
al
final
cytokineschemokin
influenc
develop
th
cell
subset
help
promot
target
respons
protect
intracellular
pathogen
respons
requir
protect
solubl
antigen
allergen
toxin
consist
fact
ct
induc
secret
apc
epitheli
cell
bromand
et
al
bromand
et
al
shown
enhanc
mucos
immun
respons
coadminist
antigen
promot
pattern
plasma
igg
subclass
similar
respons
induc
ct
staat
et
al
cmi
ctl
respons
could
also
induc
nasal
administ
combin
induc
cytokin
plu
gmcsf
bradney
et
al
ct
also
shown
induc
secret
epitheli
cell
mcgee
et
al
howev
contrast
nasal
deliveri
togeth
protein
antigen
promot
antigenspecif
system
immun
fail
induc
mucos
siga
antibodi
respons
thu
cytokin
induc
ct
provid
signal
mucos
siga
antibodi
respons
major
cytokin
produc
apc
respons
varieti
stimuli
cytokin
shown
induc
antibodi
nasal
coadminist
protein
vaccin
system
compart
mucos
tissu
aralandandam
et
al
boyaka
et
al
via
mechan
involv
cell
addit
nasal
marinaro
et
al
belyakov
et
al
oral
marinaro
et
al
coadministr
ct
redirect
ctinduc
respons
toward
optim
induct
ctl
mucos
hiv
peptid
vaccin
belyakov
et
al
singl
intratrach
dose
l
recent
report
increas
number
dc
cell
rat
lung
tissu
enhanc
mucos
antibodi
respons
protein
antigen
deliv
thereaft
pabst
et
al
along
line
nasal
coadministr
protein
antigen
plasmid
dna
express
l
l
promot
antigenspecif
mucos
system
antibodi
respons
kataoka
et
al
interestingli
unlik
cpg
odn
stimul
respons
l
promot
respons
kataoka
et
al
innat
molecul
secret
mucos
epithelia
also
test
determin
potenti
provid
signal
bridg
innat
adapt
mucos
immun
system
lymphotactin
lptn
c
chemokin
produc
predominantli
nk
cell
includ
tcr
iel
nasal
coadministr
lptn
protein
antigen
enhanc
antigenspecif
antibodi
respons
blood
plasma
mucos
secret
lillard
et
al
lptn
adjuv
induc
antigenspecif
cell
antibodi
subclass
lillard
et
al
anoth
cc
chemokin
rant
also
display
mucos
adjuv
activ
nasal
coadminist
protein
antigen
lillard
et
al
rant
adjuv
promot
antigenspecif
cytokin
respons
support
plasma
igg
subclass
respons
lillard
et
al
discuss
ct
lt
similar
chemokin
may
differ
effect
mucos
antibodi
cmi
respons
exampl
distinct
highli
homolog
cc
chemokin
share
affin
also
bind
well
mous
ligand
recent
studi
shown
nasal
deliv
promot
strong
plasma
igg
antibodi
well
mucos
system
cmi
respons
coadminist
antigen
lillard
et
al
hand
less
effect
adjuv
plasma
igg
antibodi
fail
induc
cmi
respons
howev
support
higher
level
mucos
siga
antibodi
lillard
et
al
highli
purifi
complex
triterpen
glycosid
isol
bark
quillaja
saponaria
molina
tree
kensil
kramer
nativ
enterotoxin
reoviru
protein
sigma
one
vaccin
formul
test
sever
parenter
vaccin
formul
livingston
et
al
kensil
kramer
report
promot
system
mucos
immun
nasal
dna
vaccin
sasaki
et
al
other
shown
also
act
adjuv
given
mice
oral
rout
interestingli
low
oral
dose
promot
mucos
siga
ab
respons
siga
antibodi
induc
high
oral
hand
stronger
respons
seen
immun
high
oral
dose
possibl
mild
deterg
activ
relat
saponin
deriv
kensil
kramer
may
enhanc
immun
respons
facilit
antigen
uptak
point
mechan
saponin
deriv
promot
mucos
immun
control
th
cell
subset
differenti
remain
determin
empir
experi
mucos
immun
result
commonli
held
view
repeat
administr
high
dose
antigen
requir
achiev
level
immun
respons
induc
system
immun
conclus
physiolog
justifi
sinc
primari
function
mucos
immun
system
prevent
overstimul
entir
immun
system
elimin
mucos
appli
antigen
denatur
acid
degrad
enzym
factor
innat
immun
intestin
peristalsi
ciliari
movement
epithelia
respiratori
tract
result
concert
interact
factor
littl
antigen
remain
absorb
therebi
stimul
induct
site
mucos
system
immun
respons
mucos
vaccinologist
devis
deliveri
system
circumv
obstacl
compar
advantag
disadvantag
mucos
antigen
deliveri
dealt
detail
cover
ensu
chapter
furthermor
emphas
result
obtain
gener
anim
model
rather
human
unavoid
limit
abil
viral
outer
capsid
protein
bind
cell
cover
mucos
induct
site
recent
exploit
devis
deliveri
system
protein
dna
possibl
polysaccharid
vaccin
see
chapter
regard
reovirus
nonenvelop
doublestrand
rna
icosahedr
virus
compos
three
serotyp
schiff
field
wide
studi
serotyp
enter
host
via
cell
fae
bind
cell
mediat
via
cterminu
minor
outer
capsid
protein
sigma
one
mah
et
al
subunit
kda
polymer
via
nterminu
form
stabl
tetram
basseldubi
et
al
incorpor
liposom
shown
allow
bind
mous
l
cell
rat
peyer
patch
ruba
et
al
likewis
bind
nalt
cell
wu
et
al
wu
et
al
major
interest
mucos
vaccin
develop
immun
dna
complex
could
overcom
low
immunogen
nake
dna
promot
elev
siga
plasma
igg
antibodi
respons
wu
et
al
protein
polysaccharid
vaccin
antigen
could
link
optim
target
cell
mucos
induct
site
howev
extrapol
strategi
human
vaccin
first
requir
determin
serotyp
reoviru
best
affin
human
cell
sinc
ag
immunogen
particul
form
solut
vulner
antigendegrad
enzym
acid
often
incorpor
vehicl
nontox
nonimmunogen
protect
vaccin
materi
degrad
enhanc
uptak
mucos
surfac
may
exhibit
adjuv
effect
see
chapter
exampl
discuss
next
gelatin
capsul
coat
substanc
eg
cellulos
acet
phthalat
dissolv
alkalin
ph
intestin
acid
ph
stomach
use
oral
deliveri
bacteri
viral
vaccin
sever
studi
perform
human
although
vaccin
given
entericco
capsul
rigor
shown
effect
free
antigen
influenza
viru
expos
acid
ph
lowli
immunogen
remain
intact
viru
place
entericco
gelatin
capsul
drop
ph
greatli
diminish
moldoveanu
et
al
mucoadhes
polym
adher
mucos
surfac
extend
time
exposur
vaccin
thu
facilit
induct
immun
respons
compound
highli
viscou
inert
polysaccharid
eldexom
carboxymethyl
cellulos
use
oral
nasal
vagin
deliveri
antigen
influenza
viru
ctb
could
promot
local
mucos
system
immun
respons
compound
consid
carbapol
polycarbophil
sodium
algin
hydroxypropyl
cellulos
use
medicin
deliveri
drug
combat
diarrhea
constip
promot
wound
heal
immunostimul
complex
iscom
cagelik
particl
gener
addit
cholesterol
quil
bark
quillaja
saponaria
molina
tree
iscom
effect
oral
deliveri
system
promot
mucos
system
immun
recent
iscom
contain
fusion
protein
compris
ova
peptid
epitop
link
highli
immunogen
given
nanogram
dose
oral
nasal
rout
mowat
et
al
interestingli
iscom
contain
enzymat
inact
mutant
protein
much
less
effect
suggest
least
part
activ
combin
vector
requir
adpribosyl
properti
mowat
et
al
biodegrad
microspher
compos
antigen
incorpor
polym
lactic
glycol
acid
use
far
extens
mucos
vaccinolog
mucos
deliveri
system
solubl
protein
viral
bacteri
glycoprotein
virus
eg
influenza
siv
given
microencapsul
vaccin
oral
intratrach
human
monkey
rodent
mani
studi
microspher
prefer
deliveri
system
stabil
allow
protect
incorpor
antigen
acid
enzym
eas
size
rapid
biodegrad
modifi
fabric
process
nontox
result
unparallel
record
safeti
biodegrad
novel
molecular
method
allow
product
subunit
vaccin
transgen
plant
see
chapter
plant
engin
synthes
assembl
adjuv
one
antigen
retain
bcell
epitop
haq
et
al
tacket
et
al
yu
langrid
feed
transgen
potato
tuber
shown
induc
system
mucos
immun
respons
mice
haq
et
al
human
tacket
et
al
order
circumv
potenti
denatur
antigen
cook
recombin
plant
requir
cook
banana
tomato
develop
mani
bacteri
viral
vector
salmonella
e
coli
mycobacteria
lactobacilli
polio
adeno
rhinomengo
influenza
vaccinia
canarypox
virus
use
variabl
success
anim
model
see
chapter
recombin
bacteri
vector
ie
salmonella
typhi
licens
unit
state
use
oral
vaccin
tabl
june
coldadapt
live
influenza
vaccin
ie
flumist
approv
nasal
vaccin
human
tabl
despit
signific
advanc
studi
requir
determin
optim
mucos
immun
protocol
enhanc
express
futur
live
recombin
vaccin
diminish
respons
vector
prevent
elimin
immun
mechan
fact
vector
deliveri
limit
former
pathogen
subject
attenu
mutat
genom
delet
nonpathogen
strain
bacteria
lactobacilli
evalu
vaccin
deliveri
system
instanc
host
immun
respons
develop
recombin
vector
transgen
use
differ
recombin
vector
prime
boost
could
help
reduc
potenti
immun
vector
extens
experi
perform
anim
clearli
indic
oral
nasal
exposur
certain
antigen
eg
myelin
basic
protein
ovalbumin
cartilag
type
ii
collagen
induc
state
unrespons
system
compart
upon
system
immun
see
chapter
recent
exist
phenomenon
document
human
immun
oral
krau
et
al
nasal
waldo
et
al
keyhol
limpet
hemocyanin
klh
subsequ
system
immun
antigen
clearli
demonstr
boostabl
mucos
system
humor
immun
respons
suppress
tcell
prolifer
delayedtyp
hypersensit
dth
reaction
call
split
toler
consequ
unlik
oral
nasal
appli
vaccin
would
induc
state
unrespons
humor
arm
immun
respons
consid
fact
vaccin
use
far
human
medicin
exhibit
protect
effect
induct
specif
antibodi
rather
ctl
possibl
induc
toler
mucos
exposur
minim
nevertheless
suppress
perhap
respons
would
counterproduct
immun
strategi
whose
aim
induc
protect
cellmedi
respons
eg
hiv
howev
emphas
suppress
cellmedi
respons
occur
antigen
administ
mucos
rout
previous
anim
sharp
contrast
initi
system
prime
ensu
band
tcell
respons
suppress
subsequ
mucos
immun
fact
basic
impact
unfortun
often
disregard
therefor
assum
ongo
system
immun
respons
particularli
autoimmun
charact
suppress
mucos
exposur
antigen
elicit
preced
system
respons
contrari
assumpt
chase
dramat
demonstr
cellmedi
respons
induc
system
immun
anim
haptencarri
suppress
oral
administr
antigen
vein
dth
reaction
poison
ivi
poison
oak
suppress
oral
administr
dri
leav
variou
extract
human
review
see
steven
klingman
recent
studi
clearli
demonstr
ongo
vigor
respons
induc
system
immun
autoantigen
refractori
suppress
nasal
oral
administr
antigen
review
see
studi
recent
extend
human
indic
ongo
humor
cellular
respons
induc
system
immun
klh
suppress
subsequ
extend
ingest
larg
dose
klh
elson
co
univers
alabama
birmingham
person
commun
summari
sequenc
system
prime
follow
mucos
boost
provid
vigor
humor
cellular
immun
respons
mucos
system
compart
minim
danger
induc
toler
cellmedi
arm
immun
respons
well
establish
adjuv
requir
effect
induct
mucos
immun
less
appreci
fact
deliveri
system
andor
adjuv
also
need
enhanc
mucos
toler
effect
immunotherapeut
applic
thu
far
promis
vehicl
induc
mucos
toler
ctbthu
mucos
deliveri
ctb
chemic
link
genet
fuse
variou
autoantigen
gener
effect
method
induc
toler
mucos
administr
autoantigen
alon
exampl
oral
nasal
treatment
lowdos
ctb
chemic
conjug
genet
link
fusion
protein
myelin
basic
protein
insulin
bergerot
et
al
collagen
ii
tarkowski
et
al
andor
select
peptid
deriv
antigen
could
total
markedli
suppress
develop
experiment
autoimmun
enceph
eae
type
diabet
collageninduc
arthriti
respect
addit
prolong
oral
treatment
low
dose
allergen
conjug
ctb
markedli
suppress
ige
antibodi
respons
allerg
reaction
sensit
mice
rask
et
al
recent
mucos
induc
uveiti
could
prevent
rat
oral
administr
ctb
link
uveitogen
peptid
aa
deriv
human
heatshock
protein
hsp
phipp
et
al
mechan
underli
enhanc
oral
toler
ctbag
conjug
probabl
complex
partial
understood
induct
mucos
immun
dc
appear
also
play
critic
role
mucos
toler
viney
et
al
thu
prime
dc
may
constitut
major
step
induct
immun
respons
mucos
deliv
antigen
develop
activ
adapt
respons
versu
toler
could
dictat
addit
stimuli
includ
cytokin
costimulatori
molecul
exampl
treatment
differ
ctbag
conjug
fusion
protein
report
promot
activ
tolerogen
apc
suppressiveregulatori
cell
mucos
tissu
drain
lymph
node
oral
feed
ctb
shown
prevent
cure
experiment
coliti
mice
reduct
product
within
larg
intestin
boiriv
et
al
furthermor
toler
also
shown
downregul
chemokin
includ
rant
chemokin
stimul
adapt
immun
lillard
et
al
wateri
diarrhea
induc
nativ
enterotoxin
major
safeti
concern
identifi
thu
far
oral
vaccin
seen
nontox
mutant
develop
overcom
toxic
unfortun
nontox
enterotoxin
mutant
gener
poor
adjuv
oral
vaccin
although
often
retain
adjuvant
nasal
coadminist
vaccin
antigen
review
safeti
immunogen
efficaci
oral
rhesushuman
reassort
vaccin
candid
rotaviru
work
group
advisori
committe
immun
practic
acip
center
diseas
control
prevent
cdc
note
case
intussuscept
among
vaccine
occur
first
week
postvaccin
case
among
placebo
recipi
margaret
et
al
none
case
judg
clinic
studi
investig
directli
attribut
vaccin
product
withdrawn
market
thu
better
method
need
analyz
predict
potenti
toxic
oral
vaccin
nasal
caviti
anatom
close
olfactori
nervesepithelium
one
olfactori
bulb
ob
recent
studi
examin
whether
addit
nalt
ct
adjuv
could
target
tissu
central
nervou
system
ct
b
subunit
ctb
enter
one
ob
persist
day
although
neither
molecul
present
nalt
beyond
hour
nasal
deliveri
van
ginkel
et
al
uptak
olfactori
region
monosialogangliosid
depend
nasal
vaccin
itt
togeth
unlabel
ct
adjuv
result
uptak
one
ob
wherea
itt
alon
penetr
cn
studi
suggest
molecul
like
ct
target
one
retrogradetransport
ob
may
promot
uptak
vaccin
protein
olfactori
neuron
rais
concern
role
molecul
target
neuron
tissu
mucos
immun
van
ginkel
et
al
target
cn
tissu
nasal
administ
bacteri
enterotoxin
possibl
relat
higher
incid
bell
palsi
facial
paresi
among
volunt
nasal
vaccin
trial
nativ
lt
mucos
adjuv
thu
seriou
advers
event
report
approxim
subject
particip
clinic
safeti
trial
nonliv
nasal
flu
vaccin
nasalflu
case
bell
palsi
trigemin
neuralgia
develop
facial
paresi
furthermor
five
case
bell
palsi
spontan
report
among
approxim
recipi
nasalflu
vaccin
withdrawn
market
wwwniaidnihgovdmidentericintranasalhtm
tabl
recent
approv
trival
flumist
coldadapt
live
influenza
vaccin
demonstr
nasal
rout
remain
viabl
choic
deliveri
care
devis
mucos
vaccin
like
hiv
aid
year
ago
recent
worldwid
outbreak
sever
acut
respiratori
syndrom
sar
dramat
remind
us
infecti
diseas
remain
major
global
threat
longer
restrict
develop
countri
select
popul
newli
discov
coronaviru
respons
sar
kuiken
et
al
infect
host
via
mucos
tissu
respiratori
tract
mucos
antibodi
cmi
respons
could
provid
host
lifesav
protect
case
inhal
anthrax
relat
bioterror
attack
unit
state
octob
novemb
jernigan
et
al
guarner
et
al
demonstr
import
mucos
tissu
portal
entri
pathogen
agent
use
bioterror
agent
regard
transmiss
categori
bioterrorist
agentsdiseas
list
cdc
occur
either
inhal
ingest
understand
mechan
adjuv
control
mucos
antibodi
cmi
respons
greatli
improv
past
decad
fact
know
pattern
recognit
togeth
innat
factor
cytokin
chemokin
apc
function
dc
crucial
initi
mucos
immun
new
improv
deliveri
system
critic
use
new
mucos
vaccin
nasal
flumist
vaccin
adp
ribosyltransferas
activ
bacteri
enterotoxin
potenti
toxic
investig
mucos
vaccin
recent
knowledg
nasal
vaccin
potenti
bind
neuron
foster
research
safeti
mucos
vaccin
help
design
safer
vaccin
administ
nasal
mucos
rout
recent
approv
flumist
vaccin
could
first
long
list
newgener
mucos
vaccin
